The Pivotal Gap

The decision that determines your pivotal is made one inflection earlier than you think — during follow-up, not after the data.

TL;DR

1. The industry-mean gap between Phase 2 completion and Phase 3 start is 30.3 months — not the one or two quarters most first-time sponsors carry in their runway model (DiMasi, Grabowski & Hansen, J. Health Economics, 2016).
2. A post-Phase-2 raise typically buys 18–24 months of runway. The gap is longer than the cash. That is an arithmetic problem, not a sentiment problem.
3. The levers that compress the gap — protocol and statistical-analysis lock, pivotal partner capacity, and the raise itself — are pulled at the End-of-Phase-2 (EOP2) meeting, which by FDA's own guidance happens before major Phase 3 commitments, i.e. before the readout you are waiting on.
4. A pivotal costs a median $19.0M ($41,117 per patient; oncology runs $25–40M+), and you must have that money committed before first-patient-in (Moore et al., JAMA Intern Med, 2018).
5. Every day of slip near the value inflection is worth ~$500,000 in deferred sales, against ~$40,000/day just to keep a Phase 3 running (Schuhmacher et al., Ther. Innov. Regul. Sci., 2024).
6. More than one-third of biotechs now hold under a year of cash — the highest in at least six years (EY, 2024). In that market, the sponsor who treats the pivotal as a post-readout procurement event raises the Phase 3 money from the weakest possible position.

1. The belief

Ask a first-time, single-asset team how the next 18 months go and you get a clean story: finish Phase 2, read out, and — if the data are good — run an RFP, pick the best-fit CRO, and start the pivotal. The readout is the milestone. Everything that matters is downstream of it. Runway is budgeted against a short hop from data to dosing.

It is a reasonable story. It is also off by about two years.

2. The number

The mean elapsed time from Phase 2 completion to Phase 3 start is 30.3 months. That figure is not a soft benchmark — it comes from the most-cited cost-of-development dataset in the industry, covering compounds at the 50 largest firms (DiMasi et al., 2016). The same dataset puts mean Phase 2 duration at 37.9 months and Phase 3 at 45.1. The "gap" is its own phase, and it is the length of a clinical phase.

Now set it next to the balance sheet.

Input	Value	Source
Mean Phase 2 → Phase 3 gap	30.3 months	DiMasi et al. 2016
Typical post-Phase-2 runway	18–24 months	EY / industry
Median pivotal trial cost	$19.0M (IQR $12.2–33.1M)	Moore et al. 2018
Median cost per patient	$41,117	Moore et al. 2018
Value of a delay-day (lost sales)	~$500,000	Schuhmacher et al. 2024
Direct cost to run a Phase 3	~$40,000/day	Schuhmacher et al. 2024
Phase 2 → Phase 3 transition rate	23–25%	Dowden & Munro 2019
Biotechs with < 1 year of cash	> 1/3 (6-year high)	EY 2024

The gap is longer than the runway. That is the whole problem, stated in one line.

A fair objection: DiMasi's sample is large pharma — firms that are not cash-constrained and do not have to stop and raise between phases. For an emerging single-asset sponsor, the financing step sits inside the gap. So 30.3 months is not a ceiling for you. It is a floor.

3. Why the belief was right once and is wrong now

Two things changed underneath the conventional story.

First, the gap stopped being operational and became financial. When money was cheap, a positive Phase 2 reliably cleared a Phase 3 raise, and the gap was just logistics. It is now a survival window: with a third of the sector under a year of cash, the raise that funds the pivotal is the hard part, and it has to clear during the gap — while you are burning and have no new data to sell. The sponsors who survive this are tying capital to lead-asset milestones and raising ahead of the readout, not after it.

Second, the design-locking decision moved upstream of the readout by regulation. The EOP2 meeting — where the FDA agrees your endpoint, your powering, and your trial design — is meant to happen before you commit major Phase 3 resources. The protocol and SAP that determine what the pivotal costs and whether it can win are fixed there. And the partner that can execute it on the timeline you need has finite capacity that is booked in advance — the CRO that ran your Phase 2 does not necessarily carry a pivotal. By the time the data print, the decisions that set the gap's length have either been made or been missed.

The belief treats the readout as the starting gun. The mechanism says the race was half-run before it fired.

4. The worked scenario

Take the modal sponsor in this set: a first-pivotal oncology company that raised $70M after Phase 2, burning ~$3.5M/month — about 20 months of runway. Phase 2 reads out in two quarters. The pivotal will cost ~$30M (oncology, mid-range), and that money has to be committed before first-patient-in.

Base case — the belief runs true. Readout lands positive. A six-month RFP-and-startup gets to first-patient-in by month 6 post-readout; the positive data clear a step-up financing that funds the pivotal. Runway holds. This is the plan in the deck.

Slip case — the gap runs true. The team starts the pivotal partner and design work only after the readout. EOP2 scheduling plus FDA feedback runs 3–4 months; RFP and partner selection 3–6; contracting and site activation 6–9. Done well, that is 12–18 months to first-patient-in — and the DiMasi mean is 30. Call it 18. At $3.5M/month, $63M is consumed before a single pivotal patient is dosed, on a $70M balance. The Phase 3 raise now happens with the cash nearly gone and no pivotal progress to show — a distressed bridge or a down-round, exactly when ~$500K/day of eventual value is already leaking out the back.

The gap between the two cases is not the science. The data were identical. The gap is when the partner, the design, and the raise were triggered — and that decision was available a full readout earlier.

The decision this quarter: rebuild the runway model against a 30-month gap, not a six-month one, and pull the EOP2 / design / partner / raise sequence forward into follow-up. Compressing the gap from ~30 months toward ~12 is the difference between raising on momentum and raising on fumes.

5. It's already happening

Company	What happened	What it shows
IO Biotech	Cash fell from $211.5M (YE2021) to $30.7M (Sep 2025) across its Phase 3 window; readout slipped to Q3 2025; Chapter 7 liquidation in March 2026	The window drains an under-capitalized sponsor — no buffer left when data land (the pivotal also missed; cited for the runway drain)
Nanobiotix	Cut R&D and froze hiring specifically to bridge the gap between cash runway and Phase 3 data	The gap as a survival event, not a logistics line
PDS Biotech	Re-cut its Phase 3 to an interim PFS endpoint under cash pressure to shorten and cheapen it	Pivotal design is a cash decision, made in the window — at EOP2, not after
Verrica	Disclosed in filings it might "delay the initiation of our Phase 3" absent financing	The gap stated, on the record, as a financing-contingent risk
Trevi	Raised $100M ahead of its Phase 2b readout	The counter-move: price the gap correctly and raise before the data

The pattern is consistent. The companies that struggle treat the gap as something that starts at the readout. The companies that don't, fund and design across it before the readout.

6. What a sharp operator does now

• Rebuild the runway model against a 30-month readout-to-pivotal gap, not a six-month one. If runway is under the gap, that delta is the raise you need to size now.
• Trigger the EOP2 / design / partner sequence during follow-up — book it off the expected readout date, not the actual one.
• Separate the Phase 2 CRO question from the pivotal CRO question; they are not the same capability and not necessarily the same firm.
• Tie the next raise to first-patient-in, not to the readout — the readout buys a valuation; first-patient-in buys time. Raise before the cash crosses the gap, not after.
• Benchmark the realistic gap for your TA against 30.3 months and work the date backward; every month you pull it in is ~$500K/day of value defended at the far end.

---

---

About DealVault Network. We work with emerging biotech sponsors, single-asset teams, and the operators around them on the part of the workflow that requires a fast, vetted introduction: the right pivotal CRO, the right EOP2-ready regulatory counsel, the right crossover capital before the readout — not after the cash has crossed the gap. Selective mandates. Discreet routing.

Recent work. Hippocratic AI · 2 partners signed in 60 days. Connect Group · $105K added in 90 days. Crawford Thomas · $100K in 6 months.

Get in touch. ritvik@dealvaultnetwork.com